BiotechTube
ReGenTree

ReGenTree

San Diego, United States· Est.
regentreellc.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

ReGenTree is a private, clinical-stage biotech developing ophthalmic therapies based on the regenerative protein Thymosin β4 (Tβ4). The company is advancing programs for dry eye syndrome and neurotrophic keratopathy, with a Phase 3 trial for the latter indication underway. As part of the broader HLB corporate network, it benefits from shared resources and regional development expertise, particularly in South Korea. The company is currently pre-revenue, with its value hinging on the clinical and regulatory success of its lead Tβ4 candidate.

Ophthalmology

Technology Platform

Development of therapies based on the regenerative protein Thymosin β4 (Tβ4) for corneal wound healing and anti-inflammatory effects in the eye.

Opportunities

The Phase 3 program for neurotrophic keratopathy addresses a severe unmet need with limited competition, offering a path to a specialized, high-value market.
Success there could validate the Tβ4 platform and provide funding and credibility to attack the massive, but crowded, dry eye syndrome market.
Integration within the HLB network provides built-in development expertise and a potential commercialization pathway in Asia.

Risk Factors

The company faces high binary risk as its entire value is tied to the clinical success of a single asset, Tβ4.
It operates in the highly competitive ophthalmic space, particularly for dry eye, against large pharmaceutical companies.
Financial and strategic dependency on the broader HLB corporate network creates vulnerability to shifts in parent-company priorities.

Competitive Landscape

In neurotrophic keratopathy, competition includes Oxervate (cenegermin-bkbj), a recombinant human nerve growth factor, and various surgical/supportive care options, making it a niche but contested space. The dry eye syndrome landscape is intensely crowded with major players like AbbVie (Restasis, Xiidra), Novartis, Bausch + Lomb, and numerous biotechs developing anti-inflammatories, secretagogues, and novel mechanisms, requiring superior differentiation for success.

More companies in Cell & Gene Therapy →More companies in United States →